120 related articles for article (PubMed ID: 29720563)
1. Pharmacology of Cardio-Oncology: Chronotropic and Lusitropic Effects of B-Type Natriuretic Peptide in Cancer Patients with Early Diastolic Dysfunction Induced by Anthracycline or Nonanthracycline Chemotherapy.
Menna P; Calabrese V; Armento G; Annibali O; Greco C; Salvatorelli E; Marchesi F; Reggiardo G; Minotti G
J Pharmacol Exp Ther; 2018 Jul; 366(1):158-168. PubMed ID: 29720563
[TBL] [Abstract][Full Text] [Related]
2. The Endogenous Lusitropic and Chronotropic Agent, B-Type Natriuretic Peptide, Limits Cardiac Troponin Release in Cancer Patients with an Early Impairment of Myocardial Relaxation Induced by Anthracyclines.
Menna P; Salvatorelli E; Armento G; Annibali O; Greco C; Marchesi F; Calabrese V; Reggiardo G; Minotti G
J Pharmacol Exp Ther; 2018 Dec; 367(3):518-527. PubMed ID: 30275150
[TBL] [Abstract][Full Text] [Related]
3. Pharmacology of Ranolazine versus Common Cardiovascular Drugs in Patients with Early Diastolic Dysfunction Induced by Anthracyclines or Nonanthracycline Chemotherapeutics: A Phase 2b Minitrial.
Minotti G; Menna P; Calabrese V; Greco C; Armento G; Annibali O; Marchesi F; Salvatorelli E; Reggiardo G
J Pharmacol Exp Ther; 2019 Aug; 370(2):197-205. PubMed ID: 31101682
[TBL] [Abstract][Full Text] [Related]
4. Cardiac Anthracycline Accumulation and B-Type Natriuretic Peptide to Define Risk and Predictors of Cancer Treatment-Related Early Diastolic Dysfunction.
Minotti G; Salvatorelli E; Reggiardo G; Mangiacapra F; Camilli M; Menna P
J Pharmacol Exp Ther; 2022 Jun; 381(3):266-273. PubMed ID: 35332076
[TBL] [Abstract][Full Text] [Related]
5. Elevated B-type natriuretic peptide levels after anthracycline administration.
Suzuki T; Hayashi D; Yamazaki T; Mizuno T; Kanda Y; Komuro I; Kurabayashi M; Yamaoki K; Mitani K; Hirai H; Nagai R; Yazaki Y
Am Heart J; 1998 Aug; 136(2):362-3. PubMed ID: 9704703
[TBL] [Abstract][Full Text] [Related]
6. Usefulness of myocardial performance index and biochemical markers for early detection of anthracycline-induced cardiotoxicity in adults.
Dodos F; Halbsguth T; Erdmann E; Hoppe UC
Clin Res Cardiol; 2008 May; 97(5):318-26. PubMed ID: 18193371
[TBL] [Abstract][Full Text] [Related]
7. Effects of brain natriuretic peptide on contraction and intracellular Ca2+ in ventricular myocytes from the streptozotocin-induced diabetic rat.
Howarth FC; Al-Shamsi N; Al-Qaydi M; Al-Mazrouei M; Qureshi A; Chandranath SI; Kazzam E; Adem A
Ann N Y Acad Sci; 2006 Nov; 1084():155-65. PubMed ID: 17151299
[TBL] [Abstract][Full Text] [Related]
8. Plasma B-type natriuretic peptide levels in systolic heart failure: importance of left ventricular diastolic function and right ventricular systolic function.
Troughton RW; Prior DL; Pereira JJ; Martin M; Fogarty A; Morehead A; Yandle TG; Richards AM; Starling RC; Young JB; Thomas JD; Klein AL
J Am Coll Cardiol; 2004 Feb; 43(3):416-22. PubMed ID: 15013124
[TBL] [Abstract][Full Text] [Related]
9. Different compartmentation of responses to brain natriuretic peptide and C-type natriuretic peptide in failing rat ventricle.
Moltzau LR; Aronsen JM; Meier S; Skogestad J; Ørstavik Ø; Lothe GB; Sjaastad I; Skomedal T; Osnes JB; Levy FO; Qvigstad E
J Pharmacol Exp Ther; 2014 Sep; 350(3):681-90. PubMed ID: 25022512
[TBL] [Abstract][Full Text] [Related]
10. Diastolic dysfunction and natriuretic peptides in systolic heart failure. Higher ANP and BNP levels are associated with the restrictive filling pattern.
Yu CM; Sanderson JE; Shum IO; Chan S; Yeung LY; Hung YT; Cockram CS; Woo KS
Eur Heart J; 1996 Nov; 17(11):1694-702. PubMed ID: 8922918
[TBL] [Abstract][Full Text] [Related]
11. Effects of human atrial natriuretic peptide on cardiac function and hemodynamics in patients with high plasma BNP levels.
Nakajima K; Onishi K; Dohi K; Tanabe M; Kurita T; Yamanaka T; Ito M; Isaka N; Nobori T; Nakano T
Int J Cardiol; 2005 Oct; 104(3):332-7. PubMed ID: 16186065
[TBL] [Abstract][Full Text] [Related]
12. C-type natriuretic peptide increases myocardial contractility and sinus rate mediated by guanylyl cyclase-linked natriuretic peptide receptors in isolated, blood-perfused dog heart preparations.
Hirose M; Furukawa Y; Kurogouchi F; Nakajima K; Miyashita Y; Chiba S
J Pharmacol Exp Ther; 1998 Jul; 286(1):70-6. PubMed ID: 9655843
[TBL] [Abstract][Full Text] [Related]
13. B-type natriuretic peptide level in the diagnosis of asymptomatic diastolic dysfunction.
Karaca I; Gülcü E; Yavuzkir M; Dağli N; Ilkay E; Ozbay Y; Işik A; Arslan N
Anadolu Kardiyol Derg; 2007 Sep; 7(3):262-7. PubMed ID: 17785213
[TBL] [Abstract][Full Text] [Related]
14. Pharmacology at work for cardio-oncology: ranolazine to treat early cardiotoxicity induced by antitumor drugs.
Minotti G
J Pharmacol Exp Ther; 2013 Sep; 346(3):343-9. PubMed ID: 23818683
[TBL] [Abstract][Full Text] [Related]
15. Usefulness of B-type natriuretic peptide in hypertensive patients with exertional dyspnea and normal left ventricular ejection fraction and correlation with new echocardiographic indexes of systolic and diastolic function.
Mottram PM; Leano R; Marwick TH
Am J Cardiol; 2003 Dec; 92(12):1434-8. PubMed ID: 14675580
[TBL] [Abstract][Full Text] [Related]
16. Utility of B-natriuretic peptide in detecting diastolic dysfunction: comparison with Doppler velocity recordings.
Lubien E; DeMaria A; Krishnaswamy P; Clopton P; Koon J; Kazanegra R; Gardetto N; Wanner E; Maisel AS
Circulation; 2002 Feb; 105(5):595-601. PubMed ID: 11827925
[TBL] [Abstract][Full Text] [Related]
17. Hemodynamic determinants of myocardial B-type natriuretic peptide release: relative contributions of systolic and diastolic wall stress.
Maeder MT; Mariani JA; Kaye DM
Hypertension; 2010 Oct; 56(4):682-9. PubMed ID: 20713912
[TBL] [Abstract][Full Text] [Related]
18. Abnormal NT-pro-BNP levels in asymptomatic long-term survivors of childhood cancer treated with anthracyclines.
Mavinkurve-Groothuis AM; Groot-Loonen J; Bellersen L; Pourier MS; Feuth T; Bökkerink JP; Hoogerbrugge PM; Kapusta L
Pediatr Blood Cancer; 2009 May; 52(5):631-6. PubMed ID: 19127569
[TBL] [Abstract][Full Text] [Related]
19. Wall stress modulates brain natriuretic peptide production in pressure overload cardiomyopathy.
Vanderheyden M; Goethals M; Verstreken S; De Bruyne B; Muller K; Van Schuerbeeck E; Bartunek J
J Am Coll Cardiol; 2004 Dec; 44(12):2349-54. PubMed ID: 15607397
[TBL] [Abstract][Full Text] [Related]
20. Superiority of brain natriuretic peptide as a hormonal marker of ventricular systolic and diastolic dysfunction and ventricular hypertrophy.
Yamamoto K; Burnett JC; Jougasaki M; Nishimura RA; Bailey KR; Saito Y; Nakao K; Redfield MM
Hypertension; 1996 Dec; 28(6):988-94. PubMed ID: 8952587
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
